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Abstract
The Trans-Pacific Partnership (“TPP”) Agreement mandates member states to
implement a patent linkage system vested in Article 18.53. To successfully join the
TPP Agreement, Taiwan has begun the legislation of a patent linkage system by
proposing an amendment for the Pharmaceutical Affairs Act. Article 18.53 requires a
member either to adopt a notification mechanism under Paragraph 1 or to stay the
issuance of marketing approval under Paragraph 2. But, Taiwan’s proposal includes
both measures. Taiwan’ patent linkage system allows a pioneer drug company to
register patents claiming (a) a material; (b) a combination or formula; or (c)
pharmaceutical use. The scope of patentees who may benefit from the mechanism is
larger than what is required. In addition, the system requires a generic drug company
to notify the patentee at the time of filing the drug application if the generic drug
company asserts invalidity or non-infringement which the generic drug company must
prove. Furthermore, the health authority is allowed to stay the issuance of a generic
drug permit while the patentee is suing the generic drug company in the court.
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I. INTRODUCTION
The Trans-Pacific Partnership (“TPP”) Agreement was signed on February 4, 2016
in Auckland, New Zealand.1 Twelve countries, including Australia, Brunei, Canada,
Chile, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore, the United States and
Vietnam, were involved in this multilateral free trade agreement (“FTA”). 2
Like many FTAs,3 the TPP Agreement has an intellectual property chapter which
is Chapter 18.4 Chapter 18 includes many provisions collectively setting a standard
beyond the Agreement on Trade-Related Aspects of Intellectual Property Rights
(“TRIPS Agreement”).5 Article 18.53 of the TPP Agreement is a highly-criticized

1
See Rebecca Howard, Trans-Pacific Partnership Trade Deal Signed, but Years of
Negotiations Still to Come, REUTERS, Feb. 4, 2016, http://www.reuters.com/article/us-trade-tppidUSKCN0VD08S (last visited Oct. 16, 2016); see also Kevin E. Noonan, The Trans-Pacific
Partnership the Future of Global Trade or A Corporate Conspiracy Against Workers?, 8
LANDSLIDE 32, 32 (2016).
2

See Howard, supra note 1.

3 See Ping-Hsun Chen, Cross-Straits Economic Cooperation Framework Agreement,
Cross-Strait Agreement on Intellectual Property Right Protection and Cooperation, and
Implications of One-China, 36 HOUS. J. INT’L L. 59, 66-67 (2014).
4 See TPP Final Table of Contents, Office of the United States Trade Representative,
https://ustr.gov/trade-agreements/free-trade-agreements/trans-pacific-partnership/tpp-full-text
(last visited Oct. 16, 2016).
5 See Rupali Francesca Samuel, Drawn Up in Secret, the TPP’s Text Helps Big Pharma
Put Patents Over Patients, THE WIRE, (Nov. 16, 2015), http://thewire.in/15571/drawn-up-insecret-the-tpps-text-helps-big-pharma-put-patents-over-patients/ (last visited Oct. 16, 2016).
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provision that relates to “patent linkage.”6 “Patent linkage” originates from the HatchWaxman Act of 1984.7 The Hatch-Waxman Act established the Abbreviated New
Drug Application (“ANDA”) system which allows a pharmaceutical company to
apply for a marketing approval of a generic version of a previously-approved drug
without going through a full-scale experiment concerning the safety and efficacy of
the generic drug.8 But, to compromise with the benefits of pioneer drug companies,
the Hatch-Waxman Act created a cause of action for pioneer drug companies to sue
those generic drug companies for patent infringement simply because of the filing of
an ANDA.9 Australia, Canada, and Singapore also have a patent linkage system. 10
While the TPP Agreement is under the national approval proceeding in each
member state, Taiwan is eager to join the TPP Agreement. 11 Among other things, the
Executive Yuan12 announced a proposed amendment of the Pharmaceutical Affairs

6

See Brook K. Baker & Katrina Geddes, Corporate Power Unbound: Investor-State
Arbitration of IP Monopolies on Medicines-Eli Lilly v. Canada and the Trans-Pacific
Partnership Agreement, 23 J. INTELL. PROP. L. 1, 10, 10 n.43 (2015).
7 See Robert A. Armitage, The Hatch-Waxman Act: A Path Forward for Making It More
Modern, 40 WM. MITCHELL L. REV. 1200, 1201-03, 1235 (2014).
8

See Quincy (Ping-Hsun) Chen, Destroying A Pharmaceutical Patent for Saving Lives?:
A Case Study of Sanofi-Synthelabo v. Apotex, Inc., 21 ALB. L.J. SCI. & TECH. 125, 136 (2011).
9

See id. at 139-40.

See, e.g., Thomas A Faunce and Joel Lexchin, ‘Linkage’ Pharmaceutical Evergreening
in Canada and Australia, AUSTL. & N.Z. HEALTH POL’Y, June 1, 2007, available at
http://www.anzhealthpolicy.com/content/4/1/8 (last visited Oct. 16, 2016).
10

11

See Tsai Appeals to US Leaders for TPP Support, TAIPEI TIMES, (Jul. 3, 2016),
http://www.taipeitimes.com/News/taiwan/archives/2016/07/03/2003650248. Because the
United States recently elected a new President, Donald Trump, who aggressively opposed the
TPP Agreement during the campaign, the future of the TPP Agreement is very negative. See,
e.g., Tim Worstall, With Trump’'s Election the TPP Probably is Dead, Yes - As is the TTIP,
FORBES, (Nov. 11, 2016_), http://www.forbes.com/sites/timworstall/2016/11/11/with-trumpselection-the-tpp-probably-is-dead-yes-as-is-the-ttip/#18a9a7845b80 ; Sam Buckingham-Jones,
Trans-Pacific Partnership Deal not Our Only Trade Option, Steve Ciobo Says, THE
AUSTRALIAN, (Nov. 13, 2016), http://www.theaustralian.com.au/national-affairs/foreignaffairs/transpacific-partnership-deal-not-our-only-trade-option-steve-ciobo-says/newsstory/d0fa129210d05475a9bcd15df114539b. On the other hand, Japan’s intent to approve the
TPP Agreement right after the U.S. presidential election makes the issue more complicate. See,
e.g., Japan’s Parliament Approves TPP Deal, Labeled ‘Disaster’ by Trump, RT, (Nov. 10,
2016), https://www.rt.com/news/366367-japan-tpp-trump-china/; Japan Lawmakers Vote to
Ratify TPP, WALL STREET JOURNAL, (Nov. 4, 2016), http://www.wsj.com/articles/japanlawmakers-vote-to-ratify-tpp-1478256900.
12

The Executive Yuan is the executive branch of the Taiwan Government.
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Act13 (“PAA”) on August 4, 2016.14 The Proposed Amendment adds Chapter 4-1
governing a patent linkage system for generic drug permit (“GDP”) applications. 15
The Proposed Amendment has been submitted to the Legislative Yuan. 16 The
proposed patent linkage system forces a generic drug company to confront with patent
law suits brought by a pioneer drug company. To do so, the Executive Yuan also
introduced an amendment of the Patent Act. 17 The Patent Act Amendment provides a
cause of action for a pioneer company to sue a generic drug company if the latter
company files a GDP application.18
This article is intended to explore the Proposed Amendment to figure out whether
the Proposed Amendment follows Article 18.53 of the TPP Agreement or goes beyond
the minimal protection on pioneer drug companies. To answer that question, it is
necessary to interpret Article 18.53 to figure out the scope of protection. In this paper,
Part II critically reviews Article 18.53 in light of the international law principles of
treaty interpretation under Article 31(1) of the Vienna convention on the Law of
Treaties (“VCLT”). Then, Part III introduces the current Pharmaceutical Affairs Act
with respect to new drug applications and generic drug applications. The topics cover
test data submission, patent information submission, and test data protection. Finally,
Part IV analyzes the Proposed Amendment. The analysis covers the new system of
patent information submission, notification mechanism, administrative action, and
anti-competition.
It is also known as “yao-shi fa” (藥事法) in Mandarin. The official English text of the
Pharmaceutical
Affairs
Act
(“PAA”)
can
be
found
at
http://law.moj.gov.tw/Eng/LawClass/LawAll.aspx?PCode=L0030001, while the Mandarin
version can be found at http://law.moj.gov.tw/LawClass/LawAll.aspx?PCode=L0030001. The
current Pharmaceutical Affairs Act became effective on December 2, 2015 by Presidential
Order hua zong yi yi No. 10400140921 (總統華總一義字第10400140921號令). When
referring to any provisions of the PAA, this paper cites or quotes the official English text unless
the author feels that the official translation cannot reflect the meaning of a provision.
13

14 See Executive Yuan, Taiwan, The Executive Yuan Committee Passed a Proposed
Amendment
of
the
Pharmaceutical
Affairs
Act
(Press
Release),
http://www.ey.gov.tw/News_Content2.aspx?n=F8BAEBE9491FC830&s=B7A2785C56246F
BA (in Mandarin) (last visited Oct. 16, 2016).
15 See Crystal J. Chen, Draft Amendment to Pharmaceutical Affairs Act Introduces Patent
Linkage System and Revised Data Exclusivity, LEXOLOGY, (Oct. 31, 2016),
http://www.lexology.com/library/detail.aspx?g=b50d0454-39c9-4694-a827-45d6d5acfe8d.
16

See Abraham Gerber, NHI Costs Would Rise with Law Changes: Opponents, TAIPEI
TIMES,
(Sept.
24,
2016),
http://www.taipeitimes.com/News/taiwan/archives/2016/09/24/2003655834. The Proposed
Amendment
can
be
downloaded
at
http://lci.ly.gov.tw/LyLCEW/agenda1/02/pdf/09/02/01/LCEWA01_090201_00043.pdf.
17 See Crystal J. Chen, TIPO Proposed to Amend IP Laws Echoing Trans-Pacific
Partnership
Agreement,
LEXOLOGY,
(Aug.
5,
2016),
http://www.lexology.com/library/detail.aspx?g=9a7b1ae4-2b62-42ab-8382-23a01f24e6f9
[hereinafter, Chen, TIPO Proposed].
18

See Chen, TIPO Proposed, supra note 17; see also Patent Act Amendment art. 60-1, para.
1.
The
Patent
Act
Amendment
can
be
downloaded
at
http://lci.ly.gov.tw/LyLCEW/agenda1/02/pdf/09/02/01/LCEWA01_090201_00044.pdf
(in
Mandarin).
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II. TPP IP CHAPTER AND PATENT LINKAGE CLAUSE
Part II discusses the prerequisite of patent linkage and analyzes three requirements
of the patent linkage system under the TPP Agreement. The analysis follows Article
31(1) of the VCLT which provides that “[a] treaty shall be interpreted in good faith in
accordance with the ordinary meaning to be given to the terms of the treaty in their
context and in the light of its object and purpose.” 19 Accordingly, the TRIPS
Agreement and Declaration on TRIPS and Public Health are interpretation tools. 20 On
the other hand, Article 31(2) of the VCLT further provides that “[t]he context for the
purpose of the interpretation of a treaty shall comprise, in addition to the text,
including its preamble and annexes: (a) any agreement relating to the treaty which was
made between all the parties in connexion with the conclusion of the treaty[,]21 but
this paper does not consider those agreements made during the negotiations for the
TPP Agreement because of the lack of publicly-accessible information.
A. Prerequisite of Patent Linkage
Article 18.53(1) sets only one condition as to when a member state shall provide a
patent linkage system. Paragraph 1 recites:
[A] Party permits, as a condition of approving the marketing of a
pharmaceutical product, persons, other than the person originally
submitting the safety and efficacy information, to rely on evidence or
information concerning the safety and efficacy of a product that was
previously approved, such as evidence of prior marketing approval by the
Party or in another territory[.] 22
The condition has three elements. First, the marketing approval law requests an
applicant to submit the safety and efficacy information of a pharmaceutical product.23
Second, an applicant may be permitted to rely on the safety and efficacy information
previously submitted by other applicant.24 Third, the previously-submitted safety and
efficacy information was used for the marketing approval of such prior applicant’s
product.25

19

Vienna Convention on the Law of Treaties art. 31(1) (1969) (emphasis added).

See TPP Agreement art. 18.6(1) (“The Parties affirm their commitment to the Declaration
on TRIPS and
20

Public Health.”).
21

Vienna Convention on the Law of Treaties art. 31(2) (1969) (emphasis added).

22

TPP Agreement art. 18.53(1).

23

TPP Agreement art. 18.53(1)(a).

24

TPP Agreement art. 18.53(1)(b).

25

TPP Agreement art. 18.53(1)(c).
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Therefore, the patent linkage system is not required if an applicant does not rely
on any previously-submitted safety and efficacy information, or if an applicant relies
on the safety and efficacy information of a pharmaceutical product that is not
previously approved.
The patent linkage system under the TPP Agreement must be understood in the
context of data protection. Patent linkage is applied after the term of test data
protection. Under Article 18.50(1), if a previously-approved product is a new
pharmaceutical product, any latter applicant is not permitted to rely on the safety and
efficacy information of such previously-approved product for at least five years from
the date of marketing approval of such previously-approved product. Under Article
18.52, a “new pharmaceutical product” in Article 18.50(1) means “a pharmaceutical
product that does not contain a chemical entity that has been previously approved.”26
The term of test data protection for at least five years also applies to a new
pharmaceutical product defined in Article 18.50(2)(b) as a pharmaceutical product that
contains “a chemical entity that has not previously approved[.]”27
Under Article 18.51, the term of test data protection is at least eight years for a
new pharmaceutical product “that is or contains a biologic,” 28 or at least five years if
other measures are also taken. 29 A “biologic” is defined in Article 18.51(2) as to
include “at a minimum, a product that is, or, alternatively, contains, a protein produced
using biotechnology processes, for use in human beings for the prevention, treatment,
or cure of a disease or condition.”30
After the term of test data protection, a member state may permit an applicant to
rely on the safety and efficacy information of a previously-approved product. At that
time, such applicant is subject to the patent linkage system. Therefore, the patent
linkage system functions as an extension of data protection.
It should be noted that Article 18.53(1) does not require “a product that was
previously approved” to be a new pharmaceutical product as Articles 18.50 and 18.51
do.31 But, in the context of generic drug applications, a person who originally
submitted the safety and efficacy information that following generic drug companies
rely on is more likely to be a right holder of the patents claiming the previouslyapproved product.32

26

TPP Agreement art. 18.52 (emphasis added).

27

TPP Agreement art. 18.50(2)(b).

28

See TPP Agreement art. 18.51(1)(a).

29 See TPP Agreement art. 18.51(1)(b). “Other measures” are not defined in the same
provision.
30

TPP Agreement art. 18.51(2).

31

TPP Agreement art. 18.53(1).

32

See Mark Gibson, Introduction and Perspective, in PHARMACEUTICAL PREFORMULATION
FORMULATION 1, 5 (Mark Gibson ed., Informa Healthcare USA 2009), available at
http://basijmed.ir/public/vimb/books/foreign%20books/Biopharmaceutical8.pdf (last visited
Oct. 16, 2016).
AND

62

JOURNAL OF LAW AND HEALTH

[Vol. 30

B. Patent Linkage System
1. Notification Requirement
Article 18.53(1) sets three requirements for a patent linkage system. First, under
Article 18.53(1)(a), a member state must establish “a system to provide notice to a
patent holder or to allow for a patent holder to be notified prior to the marketing of
such a pharmaceutical product, that such other person is seeking to market that product
during the term of an applicable patent claiming the approved product or its approved
method of use[.]”33 A member state may choose to treat a “patent holder” broadly as
“a patent licensee or the authorized holder of marketing approval.”34
This notification requirement mandates the drug approval authority of a member
state to establish a mechanism to inform a patent holder of marketing approval of a
product associated with her patent. But, to be an eligible patent holder, the patent in
question must claim the to-be-approved product or to-be-approved treatment.35 In
other words, the patent must be a pharmaceutical formula or a treatment through use
of such pharmaceutical formula. However, in a member state which excludes from
patentability “diagnostic, therapeutic and surgical methods for the treatment of
humans” under Article 27(3)(a) of the TRIPS Agreement, 36 an eligible patent may
only be a patent claiming a pharmaceutical formula.
A patent claiming a pharmaceutical formula has a specific meaning. A
pharmaceutical formula is a composition of active pharmaceutical ingredients and
excipients.37 “Excipients” include four categories: (a) substances that “aid in the
processing of the drug delivery system during its manufacture”; (b) substances that
“protect, support or enhance stability, bioavailability or patient acceptability”; (c)
substances that “assist in product identification”; (d) substances that “enhance any
other attribute of the overall safety, effectiveness or delivery of the drug during storage
or use.”38 Thus, for purposes of patent linkage, an eligible drug patent must claim not
only active pharmaceutical ingredients and excipients of the previously-approved
drug, but also dosage forms thereof.39

33

TPP Agreement art. 18.53(1)(a) (emphasis added).

34

TPP Agreement chap. 18 n. 62.

35

Id.

36

See TRIPS Agreement art. 27(3)(a) (2017).

37

See Nishath Fathima et al., Drug-Excipient Interaction and its Importance in Dosage
Form Development, 1 JOURNAL OF APPLIED PHARMACEUTICAL SCIENCE 66, 66 (2011), available
at http://www.japsonline.com/admin/php/uploads/125_pdf.pdf (last visited Oct. 16, 2016).
38

See INTERNATIONAL PHARMACEUTICAL EXCIPIENTS COUNCIL, THE IPEC EXCIPIENT
COMPOSITION
GUIDE
2
(2009),
available
at
http://ipeceurope.org/UPLOADS/IPECCompositionGuidefinal.pdf (last visited Oct. 16, 2016).
39

See Carlos Correa, Guidelines for the Examination of Pharmaceutical Patents:
Developing a Public Health Perspective 6-9 (University of Buenos Aires, Working Paper 2006),
available at http://www.ufrgs.br/antropi/lib/exe/fetch.php?media=correa_pharmaceuticalpatents-guidelines.pdf (last visited Oct. 16, 2016).
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2. Timing Requirement
The second requirement is the timing requirement. Article 18.53(1)(b) mandates a
member state to provide “adequate time and opportunity for such a patent holder to
seek, prior to the marketing of an allegedly infringing product, available remedies in
subparagraph (c)[.]”40 Three aspects may be added to the interpretation of Article
18.53(1)(b). First, the use of “seek” indicates that only a right to seek subparagraph
(c) remedies is required, but actual granting of such remedies in every case is not
mandatory. Second, the phrase “prior to the marketing of an allegedly infringing
product” indicates that a right to seek available remedies in subparagraph (c) may be
provided before the authority grants marketing approval or between the issue of
marketing approval and actual marketing by the approval holder. That is, it is not
required to stay the proceeding of marketing approval review before the patentee seeks
mandatory remedies. Third, the “adequate time and opportunity” factor must be
considered. Thus, it may not be adequate to avail the right to seek the required
remedies just before the approval holder starts to market the allegedly infringing
product.
3. “Procedure and Remedy” Requirement
The last requirement is the “procedure and remedy” requirement. Article
18.53(1)(c) demands “procedures, such as judicial or administrative proceedings, and
expeditious remedies, such as preliminary injunctions or equivalent effective
provisional measures, for the timely resolution of disputes concerning the validity or
infringement of an applicable patent claiming an approved pharmaceutical product or
its approved method of use.”41 That is, a member state must provide judicial or
administrative proceedings. In those proceedings, an eligible patentee may move for
either preliminary injunctions or equivalent effective provisional measures. The
proceedings must be timely to resolve the issue of validity or infringement. However,
a few questions remain.
The first question is whether there exists any infringing act during the marketing
approval proceeding. If there is no infringing act, the only dispute will be validity. The
interpretation of Article 18.53(1)(c) should not go that way. Otherwise, the term
“infringement” would be void, which unlikely reflects the intent of the TPP
Agreement. Thus, it is necessary to figure out which act is an infringing act during the
marketing approval proceeding.
Under Article 28(1)(a) of the TRIPS Agreement, a patentee has exclusive rights to
prevent others from making, using, offering for sale, selling, or importing for these
purposes, her patented product.42 Or, under Article 28(1)(b) of the TRIPS Agreement,
a holder of a process patent has a right to exclude others from using her patented

40

TPP Agreement art. 18.53(1)(b) (emphasis added).

41

TPP Agreement art. 18.53(1)(c).

See TRIPS Agreement art. 28(1)(a) (“A patent shall confer on its owner the following
exclusive rights: (a) where the subject matter of a patent is a product, to prevent third parties
not having the owner's consent from the acts of: making, using, offering for sale, selling, or
importing for these purposes that product[.]”).
42
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process.43 Because the TPP Agreement does not create any new exclusive rights, the
rights of an eligible patent holder under the TPP Agreement are limited to Article
28(1) of the TRIPS Agreement. In addition, seeking a marketing approval may not be
an act of infringement under Article 18.49 of the TPP Agreement.44 Therefore, the
question becomes whether acquiring a marketing approval constitutes infringement.
A marketing approval holder has a right to market his approved drug. But, that is
not equal to infringement. Marketing may mean advertising, events, knocking on
doors, or direct mail. 45 In any case, a drug company markets its product because it
wants to sell the product to targeted customers, such as doctors, hospitals, pharmacists,
and patients. If a drug company merely promotes the availability of its product, there
may be no infringement. But, if prices are in the marketing materials, such marketing
act is more likely to constitute an “offer for sale” so as to infringe the patent. 46 It is
evident that a marketing approval holder will eventually offer a price of its drug to
potential buyers. As a result, there is a potential threat to the patent holder. A timely
resolution of the infringement issue is required when a marketing approval is granted.
The issue of validity must be accompanied. Without a valid patent, there will be no
infringement.
The second question is what “timely resolution” means. Although the TPP
Agreement does not provide any clue, the phrase may be understood in light of Article
42 of the TRIPS Agreement. Article 42 requires that “[d]efendants shall have the right
to written notice which is timely and contains sufficient detail, including the basis of
the claims.”47 Article 42 also provides that all parties “shall be duly entitled to
substantiate their claims and to present all relevant evidence.”48 Therefore, the
implementation of “timely resolution” should consider not only the interests of a
patent holder, but also a marketing approval holder’s right of due process.
The last question is the scope of “expeditious remedies.” Article 18.53(1)(c)
specifies “preliminary injunctions or equivalent effective provisional measures” as
two categories of expeditious remedies. The use of “preliminary” and “provisional”
indicates that those injunctions or measures are imposed before a court issues a final
decision regarding whether the patent is infringed or whether the patent is valid. But,
See TRIPS Agreement art. 28(1)(b) (“A patent shall confer on its owner the following
exclusive rights: … (b) where the subject matter of a patent is a process, to prevent third parties
not having the owner’s consent from the act of using the process, and from the acts of: using,
offering for sale, selling, or importing for these purposes at least the product obtained directly
by that process.”).
43

44 See TPP Agreement art. 18.49 (“Without prejudice to the scope of, and consistent with,
Article 18.40 (Exceptions), each Party shall adopt or maintain a regulatory review exception for
pharmaceutical products.”).
45 See JOHN BURNETT, CORE CONCEPTS OF MARKETING 3 (2008), available at
http://www.saylor.org/site/wp-content/uploads/2012/11/Core-Concepts-of-Marketing.pdf (last
visited Oct. 16, 2016).

See 3D Sys., Inc. v. Aarotech Labs., Inc., 160 F.3d 1373, 1379 (1998) (“As a matter of
federal statutory construction, the price quotation letters can be regarded as ‘offer[s] to sell’
under § 271 based on the substance conveyed in the letters, i.e., a description of the allegedly
infringing merchandise and the price at which it can be purchased.” (alterations in original)).
46

47

TRIPS Agreement art. 42.

48

Id.
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whether those expeditious remedies are mandatory is unclear. What factor has to be
included in the consideration of those expeditious remedies is not listed in Article
18.53.
The availability of “expeditious remedies” may be determined in view of Article
18.50(3) of the TPP Agreement. Article 18.50(3) provides that a member state “may
take measures to protect public health in accordance with: (a) the Declaration on
TRIPS and Public Health[.]”49 Although the Doha Declaration on TRIPS and Public
Health (hereinafter, “Doha Declaration”) focuses on the issue of compulsory
licensing,50 it emphases a balance between the importance of intellectual property
protection for new drug development and the concerns on drug prices. 51 Thus, public
interests should be taken into consideration when expeditious remedies are
implemented. This norm is also adopted in the United States as the Federal Circuit has
held that “[t]o obtain a preliminary injunction, a party must show ‘that it is likely to
succeed on the merits, that it is likely to suffer irreparable harm in the absence of
preliminary relief, that the balance of equities tips in its favor, and that an injunction
is in the public interest.’”52
In conclusion, the “procedure and remedy” requirement mandates procedures and
expeditious remedies for a patent holder to resolve the issue of valid or infringement
of her patent claiming the approved drug when the marketing approval is granted. But,
the procedures must balance the interests of the patent holder and marketing approval
holder. Public health must also be considered.
C. Alternative to the Patent Linkage System
Article 18.53(2) of the TPP Agreement establishes an alternative system to the
patent linkage system under Article 18.53(1). Article 18.53(2) provides:
As an alternative to paragraph 1, a Party shall instead adopt or maintain a
system other than judicial proceedings that precludes, based upon patentrelated information submitted to the marketing approval authority by a
patent holder or the applicant for marketing approval, or based on direct
coordination between the marketing approval authority and the patent
office, the issuance of marketing approval to any third person seeking to
market a pharmaceutical product subject to a patent claiming that product,
unless by consent or acquiescence of the patent holder.53

49

TPP Agreement art. 18.50(3)(a).

50 See Declaration on the TRIPS Agreement and Public Health, World Trade Organization,
DOHA WTO Ministerial (Nov. 14, 2001), ¶5, 41 I.L.M. 755 (2002) [hereinafter Doha
Declaration], https://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm
(last visited Oct. 16, 2016).
51

See Id. at ¶4.

52 Luminara Worldwide, LLC v. Liown Elecs. Co., 814 F.3d 1343, 1352 (2016) (original
alterations omitted).
53

TPP Agreement art. 18.53(2) (emphasis added).
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The phrase “an alternative to paragraph 1” indicates that a system under Article
18.53(2) is not mandatory but optional. The system is defined as a non-judicial
proceeding, so it has to be an administrative proceeding. By stating that a drug
authority “precludes, … , the issuance of marketing approval,” Article 18.53(2) does
not require the authority to deny or reject the application for marketing approval.
“Preclude” means “to make (something) impossible,” “to prevent (something) from
happening,” or “to prevent (someone) from doing something.” 54 Thus, Article
18.53(2) may merely require a stay of issuing a marketing approval.
Under Article 18.53(2), preclusion of the issuance of marketing approval may be
based on the “patent-related information” submitted by a patent holder or marketing
approval applicant. But, the definition of “patent-related information” is unclear. It
may mean at least the information of patents as required in Article 18.53(1). In
addition, preclusion may be based on “direct coordination” between the drug authority
and patent authority. The second basis is more ambiguous because the TPP Agreement
does not give any instruction on how two authorities may work together to conclude
a decision of preclusion. Therefore, it is more difficult to implement Article 18.53(2)
than Article 18.53(1).
It should be noted that by providing a system for a drug authority to preclude the
issuance of marketing approval, Article 18.53(2) reaffirms that the timing for initiating
the patent linkage system under Article 18.53(1) is the time of issuing a marketing
approval. Otherwise, Article 18.53(2) is not distinct enough as to be an alternative to
Article 18.53(1).
D. Summary
While the exact meaning of the “patent linkage” provision under the TPP
Agreement is uncertain, the above analysis may provide some insights of how to
implement the provision as follows:
(1) A patent linkage system is required only when an applicant for marketing
approval relies on the safety and efficacy information of a previously-approved drug.
(2) To enjoy the benefits of patent linkage, an eligible patent holder must own a
patent claiming a pharmaceutical formulation or method for using such
pharmaceutical formulation. But, in a member state adopting Article 27(3)(a) of the
TRIPS Agreement, only a person who holds a patent for a pharmaceutical formulation
is eligible.
(3) A patent holder must be informed of the marketing approval of a drug covered
by her eligible patent when the drug authority issues the approval.
(4) A procedure for the timely resolution of infringement or validity of the patentin-suit may be an administrative or judicial procedure. While the interests of a patentee
are primarily concerned with, the procedure must consider a marketing approval
holder’s right of due process.
(5) A right to seek expeditious remedies, such as preliminary injunctions or
equivalent effective provisional measures, is required. But, the grant of such remedies
must consider public health issues.
(6) An alternative administrative procedure may be provided where the drug
authority may preclude the issuance of marketing approval. Preclusion may be based
54

See MERIAM-WEBSTER, http://www.merriam-webster.com/dictionary/preclude (last
visited Oct. 16, 2016).
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on the patent-related information submitted by either a patent holder or marketing
approval holder. The coordination between the drug authority and patent authority
may also be a basis for preclusion.
III. DRUG PERMIT APPLICATION UNDER THE PHARMACEUTICAL AFFAIRS ACT
A. Drug Permit
The Pharmaceutical Affairs Act (“PAA”) is a multi-task law governing drugs,
medical devices, pharmaceutical companies, pharmacies and other relevant matters. 55
The PAA is administrated by the Food and Drug Administration (hereinafter, “Taiwan
FDA”).56 Chapter 4 of the PAA regulates the proceedings of registration and market
approval of medicaments. Article 39 specifically provides the proceeding of approval
of a “drug permit” (藥品許可證, yao-pin xu-ke zheng; hereinafter, “DP”).57 Paragraph
4 of Article 39 authorizes the Ministry of Health and Welfare to promulgate the
Regulations for Registration of Medicinal Products 58 (“Regulations”) to review a
DP.59 Without a DP, a company cannot manufacture or import drugs. 60 An unlicensed

55 See PAA art. 1, para. 2 (“The term ‘pharmaceutical affairs’ used in the preceding
Paragraph shall refer to medicaments, pharmaceutical firms, pharmacies and other relevant
matters.”); art. 4 (“The term ‘medicaments’ as used in this Act shall refer to drugs and medical
devices.”).
56 See About FDA, Food and Drug Administration, Ministry of Health and Wealth (June 6,
2006) http://www.fda.gov.tw/EN/aboutFDAContent.aspx?id=17&chk=ec07b726-f665-4825ba5a-7d2387a299ad (last visited Oct. 16, 2016).
57 See PAA art. 39, para. 1 (“ For the manufacturing and import of drugs, information
concerning the ingredients, source of active pharmaceutical ingredients, specifications,
functions, summary of manufacturing process, and the specification and method of testing, as
well as other related information and certificates, accompanied by labels and use instructions in
the original and Chinese languages, and samples, together with the fee paid, shall be filed with
the central competent health authority for registration and market approval. No manufacturing
or importation of such drugs shall be allowed until a drug permit license is approved and
issued.”).

It is also known as “yao-pin cha-yan deng-ji shen-cha zhun-ze” (藥品查驗登記審查準
則) in Mandarin. The official English text of the Regulations for Registration of Medicinal
Products
(“Regulations”)
can
be
found
at
http://law.moj.gov.tw/Eng/LawClass/LawContent.aspx?PCODE=L0030057,
while
the
Mandarin
version
can
be
found
at
http://law.moj.gov.tw/LawClass/LawContent.aspx?PCODE=L0030057.
58

59 See PAA art. 39, para. 4 (“The application criteria, review procedure, approval criteria,
and other matters to be complied with shall be established in the Regulations for Registration
of Medicinal Products by the central competent health authority.”).
60

See Id. at ⁋ 1.
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drug is considered a fake or counterfeit drug. 61 A person who manufactures, imports,
or sells unlicensed drugs is criminally liable.62
B. Submission of Test Data for a New Drug
A “new drug” is defined in Article 7 of the PAA as “a drug which can be
recognized through the examination of the central healthcare authority as a new
compound, composition with a new therapeutic effect, or dosage form with a new
administration.”63 Article 38-1 of the Regulations requires a “new drug permit”
(“NDP”) applicant for a new compound to submit test data of either of two
categories.64 The first-category data comes from Phase I conducted during the research
period in Taiwan and Phase III simultaneously conducted in a foreign country. 65 The
second-category data comes from Phase II and Phase III conducted simultaneously in
Taiwan and foreign country.66 The Regulations also provide the experimental
requirements for Phases I, II, and III.67 Phase I is considered experimental in its nature
and requires a pharmacokinetics study or pharmacodynamics study.68 In both studies,
the number of tested people is at least ten in principle. 69 Phase II is clinical testing
where the number of tested people is at least twenty in principle. 70 Phase III is known
as a pivotal trial where the number of tested people is at least eighty in principle so as
to sufficiently show that the test result in Taiwan is similar to that in the foreign
country.71 The testing conditions of Phases I, II, or III may be modified by the Taiwan
FDA.72 Tested people must be selected from Taiwanese people.
Alternatively, Article 38-2 of the Regulations allows an applicant to rely on drug
approval issued by Germany, United States, United Kingdom, France, Japan,
Switzerland, Canada, Australia, Belgium, or Sweden. 73 But, the applicant is still
required to submit clinical testing data of Phases I, II, and III. 74 Phase I under Article

61 See Id. art. 20 (“The term ‘counterfeit drugs’ as used in this Act shall refer to the drugs
which are found to fall within any of the following circumstances after inspection or testing: 1.
The drugs are manufactured without prior approval[.]”).
62

See Id. arts. 82, 83.

63

Id. art. 7.

64

See Regulations for Registration of Medicinal Products art. 38-1 (“Regulations”).

65

See Id. art. 38-1, para. 1.

66

See Id.

67

See Id. 38-1, para. 2.

68

See Id.

69

See Id.

70

See Id.

71

See Id.

72

See Id.

73

See Id. art. 38-2, para. 1.

74

See Id. art. 38-2, para. 2.
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38-2 is the same as Phase I under Article 38-1.75 Phases II & III under Article 38-2
should be conducted in medical centers of multiple countries, but the number of tested
Taiwanese people must meet either of two conditions. 76 The first condition requires
that the number for Phase II is at least twenty in principle and that number for Phase
III is at least eighty in principle.77 The second condition requires in both Phase II and
Phase III, the number of tested Taiwanese people should amount to at least ten percent
of the total tested people around the different medical centers. 78
In addition, Article 38-2 of the Regulations requires a second type of Phase III
clinical data.79 While the second type should be conducted in medical centers of
multiple countries, the countries must include one of Germany, United States, United
Kingdom, France, Japan, Switzerland, Canada, Australia, Belgium, and Sweden. 80 If
the number of total tested people is above or equal to two hundreds, the number of
Taiwanese tested people should be at least thirty in principle or amount to at least five
percent of the total tested people.81 If the number of total tested people is below two
hundreds, the number of Taiwanese tested people should be at least ten in principle.82
The testing conditions may be modified by the Taiwan FDA. 83 Finally, the test report
for the second type must have been submitted to the Food and Drug Administration of
the United States and European Medicines Agency of the European Union as a
reference for drug approval. 84
Under Article 38-3, the testing data required by either Article 38-1 or Article 38-2
may be waived by the Taiwan FDA. 85 But, the authority may require the submission
of bridging study data.86
Currently, the examination of a drug permit application is not actually performed
by the Taiwan FDA. Instead, the Taiwan FDA has delegated its power of examination
to a non-governmental organization, the Center for Drug Evaluation (“CDE”). 87 The

75

See Id.art. 38-1, para. 2 & art. 38-2, para. 2.

76

See Regulations art. 38-2, para. 2.

77

See Id.

78

See Id.

79

See Id.

80

See Id.

81

See Id.

82

See Id.

83

See Id.

84

See Id.

85

See Regulations art. 38-3.

86

See Id.

See About Us, Center for Drug Evaluation, http://www.cde.org.tw/eng/ (“The Center for
Drug Evaluation (CDE) is a non-government and non-profit organization established by the
Department of Health (now the Ministry of Health and Welfare, MOHW) to assist the Taiwan
Food and Drug Administration (TFDA) in performing review of medical products and related
services.”).
87
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Taiwan FDA is an office receiving submissions, while the CDE examines the
scientific validity of those submissions.
C. Disclosure of Patent Information
The disclosure of patents or patent applications related to an approved new drug is
not mandatory under the PAA, while Article 40-2, Paragraph 1 requires the Taiwan
FDA to publish publicly-disclosed patent numbers or patent application numbers
submitted by a NDP applicant.88 Because the Taiwan FDA is required to publish the
patent information of an approved drug, the Taiwan FDA has promulgated “an
affidavit form of previously-disclosed patent numbers or patent application numbers”
(已揭露專利字號/案號切結書, yi jie-lu zhuan-li zi-hao or an-hao qie-jie shu).89 In
principle, a NDP applicant has to file such form when submitting her application for
drug approval. However, not all applicants follow the Taiwan FDA’s instruction. 90
D. Test Data Protection
Article 40-2 of the PAA provides the protection on test data submitted by previous
NDP applicants for a new compound.91 If the NDP holder of a previously-approved
new compound has a marketing approval for the same compound in a foreign country,
to enjoy the data protection, she must file a NDP application in three years from the
issuance of her foreign marketing approval.92 Article 40-2, Paragraph 2 prevents a
latter applicant from relying on the test data of a previously-approved new compound
for five years from the issuance of the drug permit for such new compound. 93
However, Article 40-2, Paragraph 3 allows a drug permit application for a drug that
has the same compound, same dosage form, same dosage, and same unit dose as a
previously-approved drug has possessed.94 But, such Paragraph 3 application is
permitted only after three years from the issuance of the NDP of such previouslyapproved new compound.95 Article 40-2, Paragraph 2 still applies to when a Paragraph
3 application may rely on the test data of a previously-approved new compound.96

88

See PAA art. 40-2, ⁋1.

89 See Wei Shu Yao Zi, MINISTRY OF HEALTH AND WEALTH ORDER No. 0940330797 (Oct.
24, 2005), http://www.fda.gov.tw/pda/page01Content.aspx?id=1032&chk=787b7135-d0b9467f-b572-9054f9a4af0d&param=pn%3D145.
90 See Regulations of Medicament Manufacturer Inspection, Food and Drug Administration,
Ministry
of
Health
and
Welfare,
http://www.fda.gov.tw/upload/133/2016081809343014308.xlsx.
91 PAA Art. 40.
92

See Id. art. 40-2, para. 4.

93

See Id. art. 40-2, para. 2.

94

See Id. art. 40-2, para. 3.

95

See Id.

96

See Id.
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E. “Generic Drug Permit” Application
Although the PAA does not define a “generic drug,” the Regulations do define a
“generic drug” as a drug that has the same compound, same dosage form, same dosage,
and same efficacy of a previously-approved drug.97 Therefore, in Article 40-2,
Paragraph 3 of the PAA, a drug that has the same compound, same dosage form, same
dosage, and same unit dose as a previously-approved drug may be considered as a
generic version of such previously-approved drug.98 A Paragraph 3 application is a
Taiwanese version of a generic drug application.
However, the PAA does not allow a GDP applicant to rely on her own test data.
The Proposed Amendment does not change that. As analyzed in Part II, the
prerequisite of the patent linkage system under Article 18.53 is that a GDP applicant
relies on previously-submitted test data.99 If a GDP applicant chooses to submit his
own test data, he is not subject to the patent linkage system. 100 Therefore, the PAA
and Proposed Amendment are not flexible to a generic drug company.
IV. TAIWAN’S PROPOSED PATENT LINKAGE SYSTEM
The TPP Agreement requires a member state either to adopt a notification
mechanism under Article 18.53(1) or to stay the issuance of marketing approval under
Article 18.53(2).101 But, Taiwan’s implementation of Article 18.53 includes a
notification mechanism and allows the health authority to stay the issuance of a
GDP.102 Whether the health authority may lift the stay depends on whether the patent
dispute surrounding a GDP application is resolved in favor of the GDP applicant. 103
Thus, Taiwan’s patent linkage system provides broader protection than what is
required under the TPP Agreement.
A. Patent Information Submission
The proposed patent linkage system starts with the provisions concerning “patentrelated information” mentioned in Article 18.53(2) of the TPP Agreement. 104 Article
48-3 and Article 48-5 of the Proposed Amendment condition whether one may benefit
from patent linkage on whether she timely submits patent information related to her
NDP.105 Article 48-3, Paragraph 1 provides that “if a drug permit holder of a new drug
thinks that it is necessary to submit the patent information of drug patents, she should
prepare relevant documents and information and submit them to the central health
97

See Regulations for Registration of Medicinal Products Art. 4 (2015).

98

PAA Art. 40-2, ¶ 3.

99

See id.

100

See id.

101

See TPP Agreement art. 18.53.

102

Id.

103

Id.

104

Id.

105

PAA Arts. 48-3, 48-5.
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authority in forty five days starting from the next day of her receipt of a drug
permit[.]”106 If she fails to submit the required patent information, Chapter 4-1 will
not apply.107
On the other hand, Article 48-5 provides that “if a drug permit holder of a new
drug acquires an invention patent examined and issued by the patent authority after
her drug permit was granted by the central health authority and if such invention patent
falls within the scope of drug patents under Article 48-3, Paragraph 2, she shall follow
[Article 48-4] to submit the patent information in forty five days starting from the next
day of the issuance of the patent.”108 If she fails to do so, Chapter 4-1 is not
applicable.109
The Proposed Amendment also considers existing NDP holders’ interests. 110
Article 48-21 provides that when the Proposed Amendment becomes effective, an
existing NDP holder may submit the required patent information under Article 48-4
in three months from the effectiveness of the Proposed Amendment. 111
An eligible drug patent is defined in Article 48-3 as a patent claiming (a) a material;
(b) a combination or formula; or (c) pharmaceutical use.112 The scope of “drug
patents” under Article 48-3 makes the proposed patent linkage system TPP-Plus.113
The category of “material” patents covers any patent that claims a single ingredient of
an approved drug.114 The scope of “single ingredients” covers not only active
pharmaceutical ingredients but also excipients.115 On the other hand, an eligible patent
under the TPP Agreement is a patent claiming the approved product composed of
active pharmaceutical ingredients and excipients.116 Hence, the Proposed Amendment
enlarges the scope of eligible patent holders beyond what is required by the TPP
Agreement.
The required patent information of a drug patent is vested in Article 48-4. For each
drug patent, a NDP holder basically has to submit three pieces of information: (a) the
patent number; (b) the last date of the term of protection; (c) the patent owner’s name
or title, nationality, and residence, domicile or business place. 117 If a drug patent claims
pharmaceutical use of a drug, a NDP holder has to identify claim numbers.118 If a drug
patent is licensed exclusively and if such exclusive license is recorded in the patent
106

PAA Art. 48-3, ¶ 1.

107

See PAA Art. 48-3, ¶ 1.

108

PAA Art. 48-5.

109

See id.

110

PAA Art. 48-21.

111

See id.

112

See id.

113

See PAA Art. 48-21.

114

Id.

115

Id.

116

See supra Part II.B.1.

117

See PAA Art. 48-4, ¶ 1.

118

See id.

2017]

ANALYSIS OF PROPOSED TPP-RELATED SYSTEM

73

authority, the (c) information of the exclusive licensee is required. 119 If the owner or
exclusive licensee of a drug patent does not reside, domicile, or have a business place
in Taiwan, the (c) information of her agent is required. 120 Last, if a NDP holder is not
the owner or exclusive licensee of the drug patent, when submitting the required patent
information, she should acquire a consent from the owner or exclusive licensee. 121
The required patent information of a drug patent may be corrected by a NDP
holder.122 Under Article 48-6, a NDP holder should apply for an amendment of patent
information if any of the following conditions have occurred: (a) the patent authority
grants and announces the extension of the term of protection; (b) the claims have been
amended and published; (c) the revocation of the drug patent has been finalized; (d)
the drug patent has expired; (e) the information of the patent owner, exclusive licensee,
or agent has changed.123 If a NDP holder is not the owner or exclusive licensee of a
drug patent, such amendment should be permitted by the patentee or exclusive
licensee.124 Furthermore, a NDP holder is required to file an amendment in forty-five
days from the next day of the occurrence of any of those five conditions. 125 But, there
is no negative consequence if she fails to do so.
The public may challenge the correctness of the required patent information. 126
Article 48-7 provides that any person may notify the Taiwan FDA of any of the
following incidents: (a) the documented drug patent has nothing to do with the
approved drug; (b) the documented drug patent does not claim a material, combination
or formula, or pharmaceutical use; (c) errors exist in the patent information; (d) the
NDP holder fails to comply with Article 48-6.127 Such person should submit written
reasons and evidence to support an Article 48-7 notification.128 Then, the Taiwan FDA
should forward the notification to the NDP holder in twenty days from the next day of
the filing of the notification.129 Next, the NDP holder should respond to the Taiwan
FDA with written reasons, but the NDP holder is free to decide whether to file an
amendment.130 In the end, the Taiwan FDA is not required to change the challenged
information even if it is incorrect.131 Instead, the Taiwan FDA is only mandated to

119

See id.

120

See id.

121

See PAA Art. 48-4, ¶ 2.

122

See id.

123

See id.

124

See PAA Art. 48-6, ¶ 1.

125

See PAA Art. 48-6, ¶ 2.

126

See PAA Art. 66.

127

See PAA Art. 48-7, ¶ 1.

128

See id.

129

See PAA Art. 48-7, ¶ 2.

130

See PAA Art. 48-7, ¶ 3.

131

See PAA Art. 48-7.
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publish the information submitted by the challenger under Article 48-7 and the
response submitted by the NDP holder.132
However, it is not to say that a NDP holder can document any patents he wants.
Under Article 100-1, “if a drug permit holder of a new drug submits patent information
as required by Articles 48-3 to 48-6 in a way of deception or falseness to the extent
where criminal liability is involved, he should be transferred to the judicial authority
for further proceedings.”133 Article 100-1 indicates that the falseness of the required
patent information may cause a NDP holder to be held criminally liable.134 But, Article
100-1 does not specify any crimes that may be committed.
B. Notification Made by a Generic Drug Permit Applicant
Unlike the current PAA, the Proposed Amendment formally recognizes generic
drug applications. While the Proposed Amendment does not define a “generic drug,”
it does use the term “generic drug permit” in several provisions related to the patent
linkage system.135
Article 48-9 provides that “[w]hen applying for a drug permit, with respect to the
patents documented by a [NDP] holder for the approved new drug, an applicant for a
[GDP] should declare to the central health authority” any of the four situations. 136 The
first situation is that “no patent information is documented for such new drug.” 137 The
second situation is that “the patents corresponding to such new drug have expired.”138
When a declaration of the first or second situation is made, a GDP will be issued after
the Taiwan FDA completes the examination of such GDP application and concludes
that all requirements are satisfied.139 The third situation is that “after the patents
corresponding to such new drug expired, the drug permit is issued by the central health
authority.”140 When a declaration of the third situation is made, even though all
requirements are met, a GDP will not be granted until the documented patents
expire.141
The fourth situation is that “the patents corresponding to such new drug should be
revoked, or the generic drug for the drug permit application does not infringe the
patents corresponding to such new drug.”142 When a declaration of the fourth situation
is made, the patent linkage system will be initiated. After a GDP application is filed,
the Taiwan FDA will review whether the required data and information are
132

See PAA Art. 48-8.

133

PAA Art. 100-1.

134

See id.

135

See generally PAA.

136

See PAA Art. 48-9.

137

See id.

138

See id.

139

See PAA Art. 48-10.

140

See PAA Art. 48-9.

141

See PAA Art. 48-11.

142

See PAA Art. 48-9.

2017]

ANALYSIS OF PROPOSED TPP-RELATED SYSTEM

75

complete.143 If the submitted data meets the requirements, the Taiwan FDA will serve
a notification of completeness of data submission to the GDP applicant. 144
When a declaration of the fourth situation is made, Article 48-12 requires a GDP
applicant to serve a written notification to the NDP holder and Taiwan FDA in twenty
days starting from the next day of the GDP applicant’s receipt of the completeness
notification.145 If the NDP holder does not own the patent or is not licensed
exclusively, an Article 48-12 notification must also be served on the patentee or
exclusive licensee.146 The written notification must include reasons and evidence of
invalidity or non-infringement.147 If the GDP applicant fails to timely serve an Article
48-12 notification, the Taiwan FDA will reject the GDP application. 148
As analyzed in Part II, the proper timing for a notification under Article 18.53(1)
is the health authority’s granting of marketing approval. 149 But, the Taiwan’s approach
requires a notification to be delivered by a GDP applicant to a patentee or exclusive
licensee when the GDP application is filed. 150 The GDP applicant is also required to
show why the patent at dispute is invalid or not infringed. 151 That is, the burden of
proof is imposed on the GDP applicant who is a potential patent infringer.
C. Stay of Issuance of a Drug Permit to a GDP Applicant
The Proposed Amendment introduces a mechanism where the Taiwan FDA may
stay issuance of a drug permit to a GDP applicant. Under Article 48-13, the mechanism
is controlled by the patentee or exclusive licensee. 152 After the patentee or exclusive
licensee receives an Article 48-12 notification, he must sue the GDP applicant for
infringement of any documented patents in forty-five days starting from the next day
of the receipt of the Article 48-12 notification.153 Article 48-13 further provides that
the period of forty-five days runs from the receipt by the patentee or exclusive
licensee, whoever receives the Article 48-12 notification later.154 The patentee or
exclusive licensee must notify the Taiwan FDA of the filing of such law suit. 155
Meanwhile, Article 48-13 mandates the Taiwan FDA not to issue a drug permit to
the GDP applicant in fifteen months starting from the next day of the NDP holder’s
143

See PAA Art. 48-12.

144

See id.

145

See PAA Art. 48-12, ¶ 1.

146

See id.

147

See PAA Art. 48-12, ¶ 2.

148

See PAA Art. 48-12, ¶ 3.

149

TPP Agreement art. 18.53.

150

Id.

151

Id.

152

See PAA Art. 48-13.

153

See PAA Art. 48-13, ¶ 1.

154

See PAA Art. 48-13, ¶ 3.

155

See PAA Art. 48-13, ¶ 1.
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receipt of the Article 48-12 notification.156 But, the Taiwan FDA may issue a drug
permit to the GDP applicant in any of the following situations157:
(1) The patentee or exclusive licensee does not initiate a law suit during the
required period of forty-five days.
(2) The law suit filed after the receipt of the Article 48-12 notification is not based
on a patent documented under Article 48-3, 48-5, or 48-21 before the GDP application.
(3) Courts find that all patents disputed in the law suit should have been
invalidated, or the GDP applicant wins a decision of non-infringement.
(4) All patents stated in the declaration of a fourth situation under Article 48-9
have been revoked by the Taiwan Intellectual Property Office.
(5) The patentee (or exclusive licensee) and GDP applicant have agreed to settle
the dispute.
(6) All patents stated in the declaration of a fourth situation under Article 48-9
have expired.
If the patentee or exclusive licensee wins the law suit filed under Article 48-13 and
if the winning decision is finalized in fifteen months starting from the next day of the
NDP holder’s receipt of the Article 48-12 notification, the Taiwan FDA is obligated
under Article 48-13 not to issue a GDP until the patent at dispute expires. 158 But, a
stay under Article 48-13 is only implemented once. 159 If the patent or exclusive
licensee sues the same GDP applicant for the same generic drug again with a different
documented patent not brought in the previous law suit, the Taiwan FDA will not stay
issuance of a GDP.160
Last, while the Taiwan FDA must stay issuance of a GDP, it can continue the
examination of the GDP application.161 Under Article 48-15, if the Taiwan FDA
completes the examination, it should notify the GDP applicant. 162 After receiving an
Article 48-15 notification, the GDP applicant may file to the National Health
Insurance Administration an application for inclusion of her drug product in the
national health insurance system and for price determination 163 But, the GDP applicant
is not allowed to manufacture or import the generic drug until a GDP is issued. 164
D. Exclusive Sales Period
The Proposed Amendment grants a period of exclusive sales to a GDP applicant
who has made a declaration of the fourth situation under Article 48-9, if such applicant
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eventually gets a GDP.165 During the exclusive sales period, the Taiwan FDA is
prevented from granting other GDPs for the same drug. 166 But, it should be noted that
under Article 48-20 a right of exclusive sales applies only if the drug under a GDP
was a drug of a new compound.167 If the drug was a drug of a composition with a new
therapeutic effect or a drug of a dosage form with a new administration, a right of
exclusive sales does not exist.168
Under Article 48-16, a GDP holder whose data submission has been first
considered complete by the Taiwan FDA will earn an exclusive sales period of twelve
months.169 However, the calculation of the period does not start from the receipt of a
GDP. Under Article 48-17, the period starts from actual sale of the products under
such GDP.170 The exclusive GDP holder has to report the actual sale to the Taiwan
FDA in twenty days starting from the next day of the actual sale. 171 Then, the Taiwan
FDA will determine the period including the starting date and expiration date. 172
However, in the context of multiple GDP applicants, Article 48-16 provides that if
the Taiwan FDA determines that more than one GDP applicants complete their data
submission on the same day, these GDP applicants will share an exclusive sales
period.173 In addition, the calculation of the period starts from the earliest actual sale
made by any of those GDP applicants. 174
A GDP applicant who is supposed to enjoy an exclusive sales period may lose his
right to exclusive sales, if any of the following three situations occurs with respect to
his GDP application175:
(1) During the examination of the GDP application, the declaration a fourth
situation under Article 48-9 has been withdrawn.
(2) A notification of the completion of the examination is not received in twelve
months starting from the next day of the completeness of the data submission.
(3) The patentee or exclusive licensee wins the law suit filed under Article 48-13,
and the winning decision is finalized in fifteen months starting from the next day of
the NDP holder’s receipt of the Article 48-12 notification.
If the first GDP applicant loses a right to exclusive sales, other following GPD
applicants for the same drug may earn such right.176 Article 48-16 provides that the
determination of which following GPD applicant inherits such right depends on the
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date on which their data submission is considered complete. 177 A following GDP
applicant who gets the earliest date wins the exclusive sales period.178
Last, Article 48-18 provides three situations where the Taiwan FDA may grant a
GPD to other applicants without the concerns of the existing right of sales
exclusivity.179 First, the GDP applicant who is supposed to enjoy an exclusive sales
period fails to acquire a GDP by a deadline required by the Taiwan FDA. 180 Second,
such GDP applicant has never reported the date of actual sale. 181 Third, the patents
listed in the declaration of the fourth situation under Article 48-9 have expired.182
The exclusive sales period seems to be negative to a pioneer drug company
because a generic drug company may share the market. But, the exclusivity actually
limits the competition the pioneer drug company will face. The pioneer drug company
and its rival generic drug company co-exist without any business penetrations from
other generic drug companies. That is an oligopoly where a small number of drug
companies are in the market.183 Although the drug price may drop, it will not be as
lower as what would be in perfect competition.184 Therefore, granting of an exclusive
sales period is actually positive to a pioneer drug company.
E. Anti-Competition Provision
The Proposed Amendment mandates a duty to report an agreement among a NDP
applicant, NDP holder, GDP applicant, GDP holder, eligible patentee or exclusive
licensee, if such agreement involves Chapter 4-1 affairs including drug manufacturing,
sales, and exclusive sales period.185 Article 48-19 requires parties of such agreement
to report to the Taiwan FDA in twenty days starting from the next day of the signing
date of such agreement.186 The way to report and the content of such report are subject
to the regulations made by the Taiwan FDA. 187 Failure to report such agreement may
result in an administrative monetary penalty imposed on the parties to such
agreement.188 Finally, if the Taiwan FDA determines that such agreement is more
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likely to violate the Fair Trade Act, it will refer the case to the Fair Trade Commission
for further proceedings. 189
V. CONCLUSION
To prepare for joining the TPP Agreement, the Taiwan Government has begun to
implement a patent linkage system required under Article 18.53 of the TPP
Agreement. Taiwan’ approach is a pro-patentee mechanism. The mechanism allows a
NDP holder to register patents claiming (a) a material; (b) a combination or formula;
or (c) pharmaceutical use. 190 The scope of patentees who may benefit from the
mechanism is larger than what Article 18.53 requires. In addition, the mechanism
requires a GDP applicant to notify the NDP holder and patentee at the time of filing
the GDP application when the applicant asserts no patents associated with the generic
drug are valid or infringed. 191 The mechanism forces the GDP applicant to prove
invalidity or non-infringement.192 Furthermore, the mechanism allows the Taiwan
FDA to stay the issuance of a GDP while the patentee is suing the GDP applicant in
the court.193 Therefore, the proposed patent linkage system may be considered as TPPPlus.
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